About: http://webisa.webdatacommons.org/394118427

Property	Value
http://www.w3.org/1999/02/22-rdf-syntax-ns#type	http://www.w3.org/ns/prov#Entity
http://www.w3.org/ns/prov#value	In addition, FDA, EMA and other regulatory agencies may not approve idelalisib for the treatment of iNHL or CLL in the anticipated timelines or at all, and any marketing approval may have significant limitations on its use.
http://www.w3.org/ns/prov#wasQuotedFrom	biospace.com